|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: GENERAL NUTRITION COMPANIES INC, 10-K, 1998-04-28 |
Next: INDIVIDUAL INVESTOR GROUP INC, DEF 14A, 1998-04-28 |
<PAGE> 1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q/A
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NO. 0-19651
MAGAININ PHARMACEUTICALS INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C>
DELAWARE 13-3445668
(STATE OR OTHER JURISDICTION OF (IRS EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
5110 CAMPUS DRIVE 19462
PLYMOUTH MEETING, PENNSYLVANIA (ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
</TABLE>
610-941-4020
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate by check mark whether the Registrant (1) has filed all reports to
be filed by Section 13 of 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
The number of outstanding shares of the Registrant's Common Stock, par
value $.002 per share, on April 22, 1998 was 22,242,890.
================================================================================
<PAGE> 2
Explanatory Note:
-----------------
The purpose of this Form 10Q/A is to file Exhibit 27,
Financial Statement Data Schedule.
<PAGE> 3
EXHIBIT INDEX
-------------
Exhibit No. Description
----------- -----------
27 Financial Statement Data Schedules
<PAGE> 4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MAGAININ PHARMACEUTICALS INC.
---------------------------------------------------------------------------
(REGISTRANT)
DATE: APRIL 28, 1998
/s/ JAY MOORIN
--------------------------------------
JAY MOORIN
CHAIRMAN, PRESIDENT AND
CHIEF EXECUTIVE OFFICER
/s/ MICHAEL R. DOUGHERTY
--------------------------------------
MICHAEL R. DOUGHERTY
EXECUTIVE VICE PRESIDENT AND
CHIEF FINANCIAL OFFICER
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
unaudited Balance Sheets as of March 31, 1998 and March 31, 1997 and the
unaudited Statements of Operations for the three months ended March 31, 1998 and
March 31, 1997 and is qualified in its entirety by reference to such financial
statements included in the Company's quarterly report on Form 10Q for the
period ended March 31, 1998.
</LEGEND>
<CIK> 0000880431
<NAME> MAGAININ PHARMACEUTICALS, INC.
<MULTIPLIER> 1000
<S> <C> <C>
<PERIOD-TYPE> 3-MOS 3-MOS
<FISCAL-YEAR-END> DEC-31-1998 DEC-31-1997
<PERIOD-START> JAN-01-1998 JAN-01-1997
<PERIOD-END> MAR-31-1998 MAR-31-1997
<CASH> 20 487
<SECURITIES> 33,000 38,574
<RECEIVABLES> 0 0
<ALLOWANCES> 0 0
<INVENTORY> 0 0
<CURRENT-ASSETS> 33,590 39,551
<PP&E> 6,435 5,772
<DEPRECIATION> 3,334 2,948
<TOTAL-ASSETS> 36,782 42,444
<CURRENT-LIABILITIES> 6,109 6,478
<BONDS> 0 0
0 0
0 0
<COMMON> 45 44
<OTHER-SE> 29,041 34,826
<TOTAL-LIABILITY-AND-EQUITY> 36,782 42,444
<SALES> 0 0
<TOTAL-REVENUES> 0 5,037
<CGS> 0 0
<TOTAL-COSTS> 0 0
<OTHER-EXPENSES> 7,130 5,572
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> 34 22
<INCOME-PRETAX> (6,650) (115)
<INCOME-TAX> 0 0
<INCOME-CONTINUING> (6,650) (115)
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> (6,650) (115)
<EPS-PRIMARY> (0.30) (0.01)
<EPS-DILUTED> (0.30) (0.01)
</TABLE>
|
|